Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study (Q21089923)
Jump to navigation
Jump to search
scientific article published in 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study |
scientific article published in 2011 |
Statements
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study (English)
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
Anette Storstein
Anette
Storstein
1 reference
1 reference
Einar K Kristoffersen
1 reference
Dipak Sapkota
1 reference
Harald Nyland
1 reference
2011
0 references
6
0 references
10
0 references
e26358
0 references
19 October 2011
1 reference
2 references
1 reference
1 reference